Trial Profile
A clinical trial of WVE-3972-01 for the treatment of amyotrophic lateral sclerosis (ALS)
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 14 Aug 2020
Price :
$35
*
At a glance
- Drugs WVE-3972-01 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors WaVe life Sciences
- 10 Aug 2020 According to a WaVe life Sciences media release, it plans to initiate clinical development with the submission of a clinical trial application (CTA) for its SNP3 program in the fourth quarter of 2020.
- 15 Dec 2017 New trial record
- 11 Dec 2017 According to a WaVe life Sciences media release, the company intends to initiate this trial in the fourth quarter of 2018.